Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1464)	12/20/2005 10:23:32 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

A dangerous looking chart--HGSI HGSI was hit hard on October 5 after it announced the results of its PII of LymphoStat-B, which didn't meet the overall primary endpoints. However, the drug was found to be safe and it reduced the symptoms of SLE at week 52 and in a subgroup of patients (about 75% of the total) it reached a level of statistical significance which made HGSI consider to plan for a PIII.<g> At any rate, with more than $4 in csh/shr and good institutional backing, it seems the stock should be able to close some of its Dec.5 downgap. bigcharts.marketwatch.com finance.yahoo.com If it can get back to $12 it would be a 50% gain from present levels, which isn't bad these days.<g> (The "analysts" consensus 1 yr. target is around $13 ) finance.yahoo.com And its longer term chart remains "interesting".<g> bigcharts.marketwatch.com Bernard